<![CDATA[Unfortunately, this article is behind a paywall.]]>Unfortunately, this article is behind a paywall. A good read if you have access. In 2023, 17% of GLP-1 agonists were prescribed for patients with no obesity/overweight/diabetes issues.

https://www.nejm.org/doi/full/10.1056/NEJMp2600300

]]>https://postcall.pub/topic/9e1ce842-abf5-4437-bec8-c7c2222347c0/unfortunately-this-article-is-behind-a-paywall.RSS for NodeFri, 01 May 2026 11:05:24 GMTWed, 29 Apr 2026 01:08:44 GMT60